Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BTK |
| Variant | C481S |
| Impact List | missense |
| Protein Effect | no effect |
| Gene Variant Descriptions | BTK C481S lies within the protein kinase domain of the Btk protein (UniProt.org). C481S demonstrates kinase activity similar to wild-type Btk (PMID: 38301010), but confers Imbruvica (ibrutinib) resistance in cell culture (PMID: 27282255, PMID: 28573668) through interference of drug binding (PMID: 25189416, PMID: 23940282). |
| Associated Drug Resistance | Y |
| Category Variants Paths |
BTK mutant BTK C481X BTK C481S |
| Transcript | NM_000061.3 |
| gDNA | chrX:g.101356177A>T |
| cDNA | c.1441T>A |
| Protein | p.C481S |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_000061.2 | chrX:g.101356177A>T | c.1441T>A | p.C481S | RefSeq | GRCh38/hg38 |
| NM_000061 | chrX:g.101356177A>T | c.1441T>A | p.C481S | RefSeq | GRCh38/hg38 |
| NM_000061.3 | chrX:g.101356177A>T | c.1441T>A | p.C481S | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06757647 | Phase II | Acalabrutinib | Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
| NCT05983965 | Phase I | Tazemetostat Acalabrutinib + Tazemetostat | Study of Tazemetostat in Lymphoid Malignancies | Terminated | USA | 0 |